€391.75
Your prediction
Vertex Pharmaceuticals Inc. Stock
Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Vertex Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | -0.240% | 1.886% | 4.634% | 1.385% | 0.013% | 22.479% | 147.598% |
| Regeneron Pharmaceuticals Inc. | -0.090% | 0.113% | -2.523% | 19.855% | -20.175% | -26.010% | 16.775% |
| IQVIA Holdings Inc. | 0.510% | -6.888% | -2.178% | 8.389% | -24.392% | -26.113% | -27.723% |
| Incyte Corp. | 0.770% | -8.571% | 4.128% | 45.257% | 1.829% | 48.476% | 21.233% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When evaluating the financial position of Vertex Pharmaceuticals Inc. (symbol: VRTX), it is evident that the company exhibits robust financial health, especially for a player in the Biotechnology & Medical Research sector. As observed from the provided financial statements, Vertex demonstrates strong revenue growth, impressive profitability, and significant cash reserves. This overall positive trend is accompanied by notable investment in research and development, which is critical for sustaining innovation in the biotech field. However, like any investment, a deeper dive into the various financial metrics is essential to identify both advantages and drawbacks.
Strong Revenue Generation: Vertex reported a total revenue of approximately $9.87 billion for 2023, showcasing healthy growth compared to previous years. The quarterly revenue growth rate of 13.3% indicates consistent demand for its products, which is promising for future sales and market expansion.
Impressive Profit Margins: The profit margin stands at around 39.5%, highlighting Vertex's ability to convert sales into profits effectively. Coupled with an operating margin of 45.2%, it reflects efficient management of operational expenses relative to revenue.
Comments
News
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks.
Vertex Pharmaceuticals (NASDAQ: VRTX) and Eli Lilly (NYSE: LLY) are two leading drugmakers that dominate their respective core therapeutic areas. Vertex has a monopoly in the market for drugs that
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year
CRISPR Therapeutics (NASDAQ: CRSP) has been anything but stable this year. Over the past six months, the stock has experienced sharp swings as the market attempts to determine whether CRISPR is
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
Pharmaceutical companies can offer investors huge returns if treatments under development become blockbuster drugs. Choosing between a speculative clinical-stage play and a dominant cash-flow engine